Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Therapeutic effects of cystamine in a murine model of Huntington's disease.

Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ.

J Neurosci. 2002 Oct 15;22(20):8942-50.

3.

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L.

Nat Med. 2002 Feb;8(2):143-9. Erratum in: Nat Med 2002 Mar;8(3):303.

PMID:
11821898
4.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

5.

Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.

Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K, Saint-Pierre M, Brownell AL.

J Neurol Sci. 2005 Apr 15;231(1-2):57-66.

PMID:
15792822
6.

Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.

Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM.

J Neurochem. 2004 Oct;91(2):413-22.

7.

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.

Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF.

J Neurochem. 2003 Jul;86(1):267-72. Erratum in: J Neurochem. 2003 Oct;87(1):272.

8.

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR.

J Neurochem. 2005 Oct;95(1):210-20.

9.

Transglutaminases - possible drug targets in human diseases.

Gentile V, Cooper AJ.

Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):99-104. Review.

PMID:
15078184
10.

Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.

Vamos E, Voros K, Vecsei L, Klivenyi P.

Biomed Pharmacother. 2010 Apr;64(4):282-6. doi: 10.1016/j.biopha.2009.06.020.

PMID:
19932584
11.

N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.

Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ.

J Neurochem. 2001 Dec;79(5):1109-12.

12.

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.

Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ.

J Comp Neurol. 2005 Oct 3;490(4):354-70.

PMID:
16127709
13.

'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.

Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino G, Moreno S, Pavone F, Oliverio S, Fesus L, Piacentini M.

Cell Death Differ. 2002 Sep;9(9):873-80.

14.

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.

Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ.

J Neurochem. 2003 Jun;85(6):1359-67.

15.

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM.

J Neurosci. 2003 Oct 15;23(28):9418-27.

16.

Transglutaminase cross-links in intranuclear inclusions in Huntington disease.

Zainelli GM, Ross CA, Troncoso JC, Muma NA.

J Neuropathol Exp Neurol. 2003 Jan;62(1):14-24.

PMID:
12528814
17.

Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.

Wang SE, Lin CL, Hsu CH, Sheu SJ, Chien CT, Wu CH.

Drug Des Devel Ther. 2015 Feb 16;9:887-900. doi: 10.2147/DDDT.S78015.

18.

Tissue transglutaminase is increased in Huntington's disease brain.

Lesort M, Chun W, Johnson GV, Ferrante RJ.

J Neurochem. 1999 Nov;73(5):2018-27.

19.

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF.

J Neurosci. 2000 Jun 15;20(12):4389-97.

20.

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF.

J Neurosci. 2002 Mar 1;22(5):1592-9.

Supplemental Content

Support Center